Protara Therapeutics Inc. (TARA), a clinical-stage biopharmaceutical company, has a clinical trial catalyst to watch next quarter related to its investigational cell therapy, TARA-002.
TARA-002, which is derived from an inactivated Group A Streptococcus pyogenes bacterium, specifically type 3, strain SU, is being developed for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs).
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.